June 26, 2015

For immediate release:

Mitsubishi Tanabe Pharma Corporation

RADICUT® inj. 30mg and RADICUT® BAG for I.V. Infusion 30mg

Mitsubishi Tanabe Pharma Corporation receives approval for additional indication for Amyotrophic Lateral Sclerosis (ALS) in Japan

Osaka, Japan, June 26, 2015 — Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Masayuki Mitsuka) announced today that it has received approval of a partial change in manufacturing and marketing approval items related to an additional indication and dosage/usage for Amyotrophic Lateral Sclerosis (ALS) for RADICUT® inj. 30mg and RADICUT® BAG for I.V. Infusion 30mg (generic name: edaravone, hereafter: RADICUT®) in Japan.

RADICUT® is a free-radical scavenger discovered by Mitsubishi Tanabe Pharma. In 2001, Mitsubishi Tanabe Pharma commenced clinical trials in Japan involving ALS patients. A series of clinical trials demonstrated that patients receiving RADICUT® showed less functional loss than patients receiving a placebo.

As a consequence from the clinical trial results, the Company filed an application for this disease with the Ministry of Health, Labour and Welfare in October 2014.

RADICUT® is also marketed as a treatment agent for the acute stage of cerebral infarction.

ALS is a progressive and intractable disease characterized by muscular atrophy and weakness. Disease progression is comparatively rapid, and if ventilators are used, survival time is said to typically be two to five years, however there is significant variation among individuals. Damage from oxidative stress caused by free radicals is thought to be one cause of the onset of ALS.

Moving forward, Mitsubishi Tanabe Pharma will work with the medical community to provide information to foster the appropriate use of RADICUT® in ALS patients.

End

⟨⟨For Details, Contact the Following Section⟩⟩
Corporate Communications Department
Tel +81-6-6205-5211